Total Payments
$148,657
2024 Payments
$11,227
Companies
11
Transactions
92
Medicare Patients
1,965
Medicare Billing
$254,918
Payment Breakdown by Category
Consulting$86,596 (58.3%)
Research$44,348 (29.8%)
Travel$12,718 (8.6%)
Other$3,390 (2.3%)
Food & Beverage$1,500 (1.0%)
Education$105.07 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $86,596 | 40 | 58.3% |
| Unspecified | $44,348 | 5 | 29.8% |
| Travel and Lodging | $12,718 | 12 | 8.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,390 | 2 | 2.3% |
| Food and Beverage | $1,500 | 28 | 1.0% |
| Education | $105.07 | 5 | 0.1% |
Payments by Type
General
$104,309
87 transactions
Research
$44,348
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $74,996 | 26 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $40,588 | 20 | $0 (2019) |
| Eisai Inc. | $13,137 | 8 | $0 (2023) |
| ABBVIE INC. | $9,026 | 18 | $0 (2024) |
| Biogen, Inc. | $3,607 | 8 | $0 (2023) |
| Lilly USA, LLC | $3,544 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,019 | 3 | $0 (2024) |
| Novo Nordisk Inc | $1,500 | 3 | $0 (2023) |
| Genentech USA, Inc. | $149.86 | 1 | $0 (2022) |
| Genentech, Inc. | $76.00 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,227 | 16 | ABBVIE INC. ($4,876) |
| 2023 | $41,006 | 28 | Eli Lilly and Company ($24,879) |
| 2022 | $5,388 | 9 | Eli Lilly and Company ($5,238) |
| 2021 | $46,461 | 7 | Eli Lilly and Company ($43,042) |
| 2019 | $1,114 | 6 | Merck Sharp & Dohme Corporation ($800.00) |
| 2018 | $18,800 | 11 | Merck Sharp & Dohme Corporation ($15,200) |
| 2017 | $24,661 | 15 | Merck Sharp & Dohme Corporation ($24,588) |
All Payment Transactions
92 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 11/19/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $66.00 | General |
| 11/19/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $26.40 | General |
| 10/29/2024 | ABBVIE INC. | QULIPTA (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/11/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $836.96 | General |
| 10/11/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $99.00 | General |
| 10/11/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/11/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/11/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 10/11/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 10/10/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $198.00 | General |
| 07/16/2024 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $2,493.75 | General |
| 04/01/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,837.50 | General |
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $1,382.96 | General |
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $328.37 | General |
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $308.03 | General |
| 11/28/2023 | Eisai Inc. | — | Consulting Fee | Cash or cash equivalent | $5,265.00 | General |
| 11/28/2023 | Eisai Inc. | — | Consulting Fee | Cash or cash equivalent | $2,583.00 | General |
| 11/28/2023 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $793.05 | General |
| 11/28/2023 | Eisai Inc. | — | Consulting Fee | Cash or cash equivalent | $57.77 | General |
| 11/06/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,625.00 | General |
| 10/27/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $3,412.50 | General |
| 10/23/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $90.20 | General |
| 10/23/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $54.77 | General |
| 10/23/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $50.21 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $43,924 | 3 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $300.00 | 1 |
| M15-566 | AbbVie, Inc. | $124.18 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 501 | 654 | $165,228 | $61,180 |
| 2022 | 5 | 536 | 749 | $180,036 | $72,015 |
| 2021 | 5 | 464 | 614 | $149,403 | $62,123 |
| 2020 | 5 | 464 | 567 | $163,437 | $59,600 |
Total Patients
1,965
Total Services
2,584
Medicare Billing
$254,918
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 182 | 223 | $81,618 | $31,259 | 38.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 86 | 86 | $39,990 | $14,231 | 35.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 73 | 78 | $20,202 | $7,000 | 34.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 100 | 204 | $14,076 | $5,355 | 38.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 49 | 51 | $9,078 | $3,234 | 35.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 11 | 12 | $264.00 | $100.80 | 38.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 233 | 305 | $101,260 | $42,426 | 41.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 71 | 71 | $33,015 | $12,010 | 36.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 92 | 104 | $24,440 | $9,272 | 37.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 113 | 239 | $16,491 | $6,537 | 39.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 27 | 30 | $4,830 | $1,770 | 36.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 209 | 279 | $88,164 | $37,726 | 42.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 90 | 95 | $21,280 | $9,036 | 42.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 55 | 55 | $24,640 | $8,946 | 36.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 77 | 151 | $10,117 | $4,285 | 42.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 33 | 34 | $5,202 | $2,129 | 40.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 209 | 290 | $87,290 | $31,273 | 35.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 66 | 66 | $28,182 | $10,245 | 36.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 116 | 137 | $29,181 | $10,235 | 35.1% |
| 99354 | Prolonged office or other outpatient service first hour | Office | 2020 | 59 | 60 | $16,740 | $6,559 | 39.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 14 | 14 | $2,044 | $1,288 | 63.0% |
About Dr. Darren Gitelman, MD
Dr. Darren Gitelman, MD is a Neurology healthcare provider based in Park Ridge, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164530804.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Darren Gitelman, MD has received a total of $148,657 in payments from pharmaceutical and medical device companies, with $11,227 received in 2024. These payments were reported across 92 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($86,596).
As a Medicare-enrolled provider, Gitelman has provided services to 1,965 Medicare beneficiaries, totaling 2,584 services with total Medicare billing of $254,918. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Behavioral Neurology & Neuropsychiatry, Behavioral Neurology & Neuropsychiatry
- Location Park Ridge, IL
- Active Since 08/25/2006
- Last Updated 04/29/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1164530804
Products in Payments
- MK-8931 (Drug) $40,588
- QULIPTA (Drug) $800.00
- Non-Covered Product (Drug) $76.00
- TSV 4mm Machined Collar MTX (Device) $15.13
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Park Ridge
Michael Rezak, Md, Phd, MD, PHD
Neurology — Payments: $399,035
Neurology $399,035
David Randall, Do, DO
Neurology — Payments: $8,652
Neurology $8,652
Dr. David Calimag, Md, MD
Neurology — Payments: $7,781
Neurology $7,781
Pavan Murty, Md, MD
Neurology — Payments: $6,735
Neurology $6,735
Dr. Danielle Rice, M.d, M.D
Neurology — Payments: $3,251
Neurology $3,251
Prashanthi Boppana, Md, MD
Neurology — Payments: $2,693
Neurology $2,693